Shares in Moderna and Novavax fell in premarket trading Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some ...
Key Takeaways The S&P 500 and Nasdaq lost ground at midday as the Trump administration's reciprocal tariffs are set to kick ...
Moderna was dealt a significant blow in the patent battle over who owns the Covid-19 vaccine last week. In the U.S., the Cambridge drug and vaccine maker hit a roadblock when the Patent Trial and ...
March 5 - Pfizer (PFE.N), opens new tab and BioNTech (22UAy.DE), opens new tab won a round in their legal battle with Moderna (MRNA.O), opens new tab over COVID-19 vaccine patents on Wednesday ...
Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For ...
HHS review of a vaccine contract sparks worries about preparedness for a potential bird flu pandemic
The contract, signed in the final days of the Biden administration, is designed to help Moderna develop and test the safety and efficacy of vaccines to protect against five subtypes of influenza ...
“The companies told the PTAB in the petitions that Moderna’s patents include ‘unimaginably broad claims directed to a basic idea.’” Patent Trial and Appeal Board (PTAB) docket entries ...
The second vaccine, developed by Moderna in partnership with the National Institute of Allergy and Infectious Diseases, got the greenlight from the FDA days later. These steps are now overlapping ...
Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft ...
In the final days of President Joe Biden’s term, Moderna MRNA won the $590 million contract to use its mRNA vaccine technology for a bird-flu vaccine. Back To Top ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback